证券代码：002675 证券简称：东诚药业 公告编号：2025-070 烟台东诚药业集团股份有限公司 关于控股子公司获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 | 药物名称 | 177Lu-LNC1009 注射液 | | --- | --- | | 剂型 | 注射剂 | | 申请事项 | 临床试验 | | 号 IND | CXHL2501029 | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，经审查， | | | 你公司提交的 注射液临床试验申请符合药 177Lu-LNC1009 | | | 品注册的有关要求，同意本品开展晚期实体瘤的临床试验。 | 一、药物的基本情况 二、药物的其他情况 1、公司在研产品 177Lu-LNC1009 注射液是一种靶向结合成纤维细胞激活蛋 白（FAP）与整合素αvβ3的双靶点放射性体内治疗药物，拟用于 FAP 阳性和整合 素αvβ3阳性的晚期恶性实体瘤患者的治疗。 2、FAP 为 II 型跨膜丝氨酸蛋白酶，高表达于许多上皮肿瘤相关成纤维细胞 (Cancer-Associat ...

Group 1 - The first batch of Shanxi Consumer Brands includes 17 brands, highlighting the province's strategy to activate consumption potential and promote industrial upgrading through brand building [1][2] - The list consists of 2 regional brands and 15 enterprise brands, covering four core areas: food, medicine, light industry, and textiles [1] - The selection process involved multiple stages, including county and enterprise applications, city-level preliminary reviews, expert evaluations, and consultations with various departments to ensure the brands have strong quality and market recognition [1] Group 2 - In the food sector, five brands reflect Shanxi's unique culinary culture, with Fenjiu representing "historical classics," Youxianduo as a "trendy newcomer," and Qinzou Huang millet as an "era premium" [2] - The pharmaceutical sector features six brands showcasing the strength of traditional Chinese medicine, with brands like Zhendong and Yabao recognized for modern pharmaceutical technology as "era premium," while Guangyuyuan is noted for its traditional crafting techniques as a "historical classic" [2] - The light industry and textile sectors include four brands that demonstrate the effectiveness of traditional manufacturing transformation, with Qiqiang showcasing the vitality of established enterprises, and Zunyi Ceramics, Dahuaglass, and "LZ" Oasis achieving breakthroughs in craftsmanship innovation, skill inheritance, and green textiles respectively [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002675证券简称：东诚药业公告编号：2025-069 烟台东诚药业集团股份有限公司 注册地址：山东省烟台市牟平区东兴大街9号21号楼 法定代表人：罗志刚 企业负责人：吴晓明 质量负责人：周洪涛 关于控股子公司获得放射性药品 生产许可证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 近日，烟台东诚药业集团股份有限公司（以下简称"公司"）收到控股子公司烟台蓝纳成生物技术股份有 限公司（以下简称"蓝纳成"）的通知，通知其收到山东省药品监督管理局下发的《放射性药品生产许可 证》。相关信息如下： 一、基本情况 企业名称：烟台蓝纳成生物技术股份有限公司 统一社会信用代码：91310000MA1H3FYU34 由于医药产品具有高技术、高风险、高附加值等特点，药品销售易受行业政策、市场环境变化等因素影 响，敬请广大投资者理性投资，注意投资风险。 三、备查文件 《放射性药品生产许可证》 特此公告。 烟台东诚药业集团股份有限公司 许可证编号：鲁RS202502 分类码：Br1 生产地址和生产范围：南京江原安迪 ...

Policy Developments - The National Healthcare Security Administration announced five typical cases of fraud involving maternity insurance funds, urging insured units and individuals to participate legally and provide accurate application materials to safeguard the fund [1] Drug and Device Approvals - Dongcheng Pharmaceutical's subsidiary received a production license for radioactive drugs, with expectations that it will not significantly impact current performance until commercial production is approved [1] - Jianyou Co., Ltd. received FDA approval for its propofol emulsion injection, with an investment of approximately RMB 73.66 million in R&D, and plans to launch the product in the U.S. soon [2] - Aihong Pharmaceutical presented clinical trial data for APL-1401 at the European Colorectal Congress, focusing on treating moderate to severe ulcerative colitis [6] - Fosun Pharma's subsidiary received approval for clinical trials of FXS887, an innovative drug for treating advanced malignant solid tumors [7] - Xinlitai received approval for clinical trials of SAL0140, a novel drug for chronic kidney disease, which could provide new treatment options if successful [8] Capital Market Activities - Lexin Medical announced that its controlling shareholder, Pan Weichao, has released the pledge on 18.71 million shares, which is 28.01% of his holdings and 8.56% of the total share capital [3] - Berry Genomics reported a decrease in the shareholding ratio of its controlling shareholder, Gao Yang, to 6.90% due to stock pledge defaults, with no significant adverse impact on the company's operations [4] - Tailong Pharmaceutical is planning a major matter that may lead to a change in control, with stock suspension expected to last no more than three trading days [5] Strategic Collaborations - JD Health and Boehringer Ingelheim Animal Health signed a strategic cooperation agreement to enhance the quality development of the domestic pet health industry through resource integration and complementary advantages [10] Regulatory Actions - Guizhou Bai Ling's actual controller, Jiang Wei, is under investigation by the China Securities Regulatory Commission for insider trading and other violations, which does not affect the company's daily operations [11]

Key Highlights - Moer Technology is set to be listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 5, 2025, following approval from the Shanghai Stock Exchange [1] - Fosun Pharma has received clinical trial approval for its innovative drug FXS887, aimed at treating advanced malignant solid tumors, with no similar small molecule inhibitors approved globally [1] - Degu Technology has terminated its major asset restructuring plans due to failure to reach an agreement on key terms with the transaction counterparties [1] - Baiwei Storage's second-largest shareholder, the National Integrated Circuit Industry Investment Fund II, reduced its stake by 4.646 million shares, representing 0.9955% of the total share capital, from 7.9033% to 6.9078% [2] - Guizhou Bai Ling's actual controller, Jiang Wei, is under investigation by the China Securities Regulatory Commission for insider trading and other violations, which does not affect the company's operations [3] - Chalco International's subsidiary has won a bid for a 3.03 billion yuan electrolytic aluminum project, which is expected to positively impact the company's future performance [4] - Grinda plans to invest approximately 79.999 million yuan in a strategic placement of shares in Muxi Integrated Circuit, representing 0.19% of the total share capital post-IPO [5] - Wanlong Optoelectronics is planning to acquire control of Zhejiang Zhongkong Information Industry Co., which is expected to constitute a major asset restructuring [7]

人民财讯12月3日电，东诚药业（002675）12月3日公告，控股子公司蓝纳成收到山东省药监督管理局下 发的《放射性药品生产许可证》。此次蓝纳成取得药品生产许可证，预期不会对公司当前业绩产生重大 影响，氟[18F]思睿肽注射液待获得药品上市批准文号后可进行商业化生产。 ...

东诚药业（002675）(002675.SZ)发布公告，近日，公司收到控股子公司烟台蓝纳成生物技术股份有限 公司(以下简称"蓝纳成")的通知，通知其收到山东省药品监督管理局下发的《放射性药品生产许可 证》。本次蓝纳成取得《药品生产许可证》，预期不会对公司当前业绩产生重大影响，氟[18F]思睿肽 注射液待获得药品上市批准文号后可进行商业化生产。 ...

智通财经APP讯， 东诚药业(002675.SZ)发布公告，近日，公司收到控股子公司烟台蓝纳成生物技术股 份有限公司(以下简称"蓝纳成")的通知，通知其收到山东省药品监督管理局下发的《放射性药品生产许 可证》。本次蓝纳成取得《药品生产许可证》，预期不会对公司当前业绩产生重大影响，氟[18F]思睿 肽注射液待获得药品上市批准文号后可进行商业化生产。 ...

格隆汇12月3日丨东诚药业(002675.SZ)公布，收到控股子公司烟台蓝纳成生物技术股份有限公司（简 称"蓝纳成"）的通知，通知其收到山东省药品监督管理局下发的《放射性药品生产许可证》。本次蓝纳 成取得《药品生产许可证》，预期不会对公司当前业绩产生重大影响，氟[18F]思睿肽注射液待获得药 品上市批准文号后可进行商业化生产。 ...

Core Viewpoint - Dongcheng Pharmaceutical announced that its subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., has received the "Radioactive Drug Production License" from the Shandong Provincial Drug Administration [1] Group 1 - The license allows the subsidiary to engage in the production of radioactive drugs, which may enhance its product offerings and market position [1] - This development indicates a regulatory approval that could lead to increased revenue opportunities for the company [1]